Compare EVR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVR | NBIX |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 15.5B |
| IPO Year | 2006 | 1996 |
| Metric | EVR | NBIX |
|---|---|---|
| Price | $259.32 | $138.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $359.38 | $180.91 |
| AVG Volume (30 Days) | 418.0K | ★ 971.6K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 54.74 | 41.95 |
| EPS | ★ 9.56 | 3.30 |
| Revenue | ★ $3,880,084,000.00 | $161,626,000.00 |
| Revenue This Year | $22.69 | $24.73 |
| Revenue Next Year | $13.31 | $13.14 |
| P/E Ratio | ★ $27.06 | $41.45 |
| Revenue Growth | 29.49 | ★ 977.51 |
| 52 Week Low | $254.31 | $122.14 |
| 52 Week High | $388.71 | $186.12 |
| Indicator | EVR | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 27.09 |
| Support Level | N/A | $125.85 |
| Resistance Level | $354.84 | $138.74 |
| Average True Range (ATR) | 8.21 | 3.94 |
| MACD | -0.04 | -1.08 |
| Stochastic Oscillator | 12.28 | 2.02 |
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.